APL-5125 is under clinical development by Apollo Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APL-5125’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APL-5125 overview
APL-5125 is under development for the treatment of colorectal carcinoma, cholangiocarcinoma, appendiceal adenocarcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, endometrial adenocarcinoma, triple negative breast cancer, ovarian cancer, and prostate cancer. The therapeutic candidate is administered through oral route in the form of capsule. It acts by targeting casein kinase II subunit alpha (CK2a).
Apollo Therapeutics overview
Apollo Therapeutics is a biopharmaceutical company that is engaged in drug discovery and drug development in the therapeutic areas of oncology, inflammatory disorders, and rare diseases. The company is headquartered in Cambridge, England, the UK.
For a complete picture of APL-5125’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
